NAUT
Nautilus Biotechnology, Inc.1.8100
-0.0900-4.74%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
228.61MP/E (TTM)
-Basic EPS (TTM)
-0.50Dividend Yield
0%Recent Filings
8-K
10-Q
Q3 FY2025 results
Nautilus Biotechnology narrowed its Q3 net loss to $13.6M from $16.4M a year earlier, thanks to a 19% drop in operating expenses to $15.5M, driven by efficiencies in R&D and lower stock-based compensation. Year-to-date, the net loss improved 15% to $45.2M, with R&D costs down 16% to $31.5M following a March workforce reduction. Cash burn eased, with operating cash use at $38.3M versus $44.8M last year, leaving $131.4M in cash and short-term investments at quarter-end. No debt weighs on the balance sheet. Progress on the proteomics platform continues, with early access launches eyed for 2026. Yet competition from established players like Thermo Fisher looms large.
8-K
Q3 loss narrows on efficiencies
Nautilus Biotechnology reported Q3 2025 net loss of $13.6 million, down from $16.4 million last year, thanks to operating expenses dropping 19% to $15.5 million from efficiencies and lower development costs. Cash reserves stood at $168.5 million, funding progress on Tau proteoform processing and a new assay for late 2026 commercialization. Early access launches in H1 2026. Platform validation remains key amid development risks.
8-K
Q2 loss narrows on cost cuts
Nautilus Biotechnology reported Q2 2025 net loss of $15.0 million, down from $18.0 million last year, thanks to operating expenses dropping 18% to $17.1 million amid cost optimizations and R&D timing shifts. The company advanced its proteome platform with a first scientific manuscript validating Iterative Mapping for unprecedented proteoform resolution, plus two new collaborations targeting Tau modifications in Alzheimer's models. Cash reserves stood at $179.5 million. Platform commercialization remains unproven.
10-Q
Q2 FY2025 results
Nautilus Biotechnology narrowed its Q2 net loss to $15.0M from $18.0M a year earlier, thanks to tighter R&D spending at $10.4M (down 16% y/y) and G&A at $6.7M (down 20% y/y), driven by workforce cuts and lower stock-based comp. Operating expenses fell 18% y/y to $17.1M, while interest income dipped to $2.1M amid a shrinking cash pile. Cash burn eased to $27.3M for the half-year, with $179.5M in cash and investments funding operations into 2026. No revenue yet, as the proteomics platform eyes a late-2026 launch. Yet competition from giants like Thermo Fisher looms large.
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
AUTL
Autolus Therapeutics plc
1.60-0.02
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
KITT
Nauticus Robotics, Inc.
0.92+0.10
LAB
Standard BioTools Inc.
1.49-0.02
MRVI
Maravai LifeSciences Holdings,
3.59-0.08
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
NKTR
Nektar Therapeutics
49.16-4.14
SEER
Seer, Inc.
1.84+0.02
TECH
Bio-Techne Corp
57.44-1.25